NSCLC: Adding Ramucirumab to Docetaxel Does Not Impair Quality of Life

Share this content:
The addition of ramucirumab to docetaxel improved clinical efficacy outcomes, without decreasing quality of life in non-small cell lung cancer.
The addition of ramucirumab to docetaxel improved clinical efficacy outcomes, without decreasing quality of life in non-small cell lung cancer.

In addition to improving clinical efficacy outcomes, adding the vascular endothelial growth factor receptor 2 (VEGFR) inhibitor ramucirumab to docetaxel did not negatively impact quality of life, symptoms, or functioning in patients with advanced/metastatic non-small cell lung cancer (NSCLC).1

The randomized, double-blind, phase 3 REVEL trial demonstrated that docetaxel plus ramucirumab improved overall survival, progression-free survival, and objective response rate in patients with advanced/metastatic NSCLC with progression after platinum-based chemotherapy.

Investigators assessed quality of life using the Lung Cancer Symptom Scale (LCSS) and clinician-reported functional status. The LCSS included 6 symptom and 3 global items measured on a 0 to 100-mm scale, with higher scores signifying greater symptom burden.

Results showed that the average LCSS total score increased from 27.3 mm at baseline to 32.0 at 30-day follow-up in the ramucirumab group, while the total score rose from 29.6 mm to 32.5 in the placebo group. Researchers found that the time to deterioration for all LCSS scores was similar between the 2 treatment arms.

The study also demonstrated that time to deterioration to ECOG performance status of 2 or higher was similar between patient arms (P = .743), as were LCSS total score (P = .932) and the Average Symptom Burden Index (P = .514).

“In addition to improvement of clinical efficacy outcomes demonstrated in REVEL, these results suggest that adding ramucirumab to docetaxel did not impair patient QoL [quality of life], symptoms, or functioning,” the authors concluded.

Reference

  1. Pérol M, Ciuleanu T-E, Arrieta O, et al. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy [published online ahead of print January 19, 2016]. Lung Cancer. doi: 10.1016/j.lungcan.2016.01.007.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters